Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

Part of paid clinical trials in Mountain View, California.

Sponsor
Envivo Bio Inc
Study ID
NCT06298409
Phase
PHASE1
Status
Recruiting

Conditions

  • Small Intestinal Bacterial Overgrowth

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • CapScan collection capsule — DEVICE
    The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.

Study Details

We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)

Key Dates

Start date
Feb 15, 2024
Status verified
Jun 2025
Primary completion
Feb 28, 2026
Completion
Feb 28, 2026

Study Design

Enrollment
34 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Primary Outcome Measure

Sampling of gut microbiota [ Time Frame: 56 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Silicon Valley GastroenterologyMountain ViewCalifornia94040
Jennifer Taufui

Find similar trials in Mountain View, CA

Related Studies